Howard John Mayson
Known title: DirectorCIK: 0001691484
Associated companies
Transaction History
| OVV | ▲ Buy | Option Exercise | 3,510 | — | 5/21/2026 | View on chart |
| OVV | ▼ Sell | Open Market | 5,000 | $262K | 3/3/2026 | View on chart |
| OVV | ▲ Buy | Option Exercise | 5,501 | — | 5/16/2025 | View on chart |
| OVV | ▼ Sell | Open Market | 4,000 | $205K | 5/31/2024 | View on chart |
| OVV | ▲ Buy | Option Exercise | 4,213 | — | 5/17/2024 | View on chart |
| OVV | ▲ Buy | Option Exercise | 8,226 | — | 3/8/2024 | View on chart |
| OVV | ▼ Sell | Open Market | 6,000 | $303K | 3/1/2024 | View on chart |
| OVV | ▲ Buy | Option Exercise | 6,074 | — | 5/18/2023 | View on chart |
| OVV | ▲ Buy | Option Exercise | 15,363 | — | 3/8/2023 | View on chart |
| OVV | ▼ Sell | Open Market | 3,000 | $137K | 3/2/2023 | View on chart |
| OVV | ▼ Sell | Gift | 2,600 | $0 | 11/14/2022 | View on chart |
| OVV | ▼ Sell | Open Market | 2,600 | $146K | 11/14/2022 | View on chart |
| OVV | ▼ Sell | Open Market | 550 | $32K | 6/1/2022 | View on chart |
| OVV | ▼ Sell | Open Market | 1,450 | $79K | 5/27/2022 | View on chart |
| OVV | ▲ Buy | Option Exercise | 4,499 | — | 5/18/2022 | View on chart |
| OVV | ▲ Buy | Open Market | 100 | — | 3/31/2022 | View on chart |
| OVV | ▼ Sell | Open Market | 300 | $14K | 3/18/2022 | View on chart |
| OVV | ▼ Sell | Open Market | 1,900 | $91K | 3/18/2022 | View on chart |
| OVV | ▲ Buy | Option Exercise | 5,414 | — | 3/8/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Ovintiv receives multiple analyst price target raises
Several research houses kept overweight or outperform ratings on Ovintiv and lifted their price targets, with Morgan Stanley moving to $71, Wells Fargo to $82, RBC to $90 and Truist to $77. The upgrades cite strong free‑cash‑flow generation from the company's Permian assets and the benefit of higher crude prices. The consensus analyst target is now about $78, above the current trading range.
Ovintiv receives multiple analyst price target raises. Several research houses kept overweight or outperform ratings on Ovintiv and lifted their price targets, with Morgan Stanley moving to $71, Wells Fargo to $82, RBC to $90 and Truist to $77. The upgrades cite strong free‑cash‑flow generation from the company's Permian assets and the benefit of higher crude prices. The consensus analyst target is now about $78, above the current trading range.